2012 Judges

HOW DO THE JUDGES SELECT THE SCRIP AWARDS WINNERS?

The Scrip Awards prides itself on its independent Judging Panel, comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.

The judges each separately consider entries from those categories that are relevant to their particular areas of
specialist knowledge, expertise and experience, ensuring a considered response to each individual submission. Each category is reviewed by at least three judges.

The judges mark each entry against the published criteria for its category, and the scores are marked out of five for each category answer. These are then collated by the Scrip Awards team to determine which entries are included in the shortlist, and the ultimate winner.

The chair of the Judging Panel reserves the right to cast any deciding vote, should the need arise. The judges’ decision is final and neither the organisers nor the Judging Panel will enter into any correspondence about the results.

Judging will take place throughout July, and the shortlist will be announced on 9 September. Details of the winners are strictly embargoed until the night but further details of all of the shortlisted entries will be published in Scrip Intelligence in the weeks leading up to the ceremony on 28 November 2012.

Richard Barker OBE Richard Barker, director general of the Association of the British Pharmaceutical Industry until May 2011, is an internationally recognised expert on both biopharmaceutical and broader healthcare issues. He is the author of 2030 – the Future of Medicine. His positions in UK healthcare include chairing both Stem Cells for Safer Medicines and the Athenaeum Group, devoted to streamlining drug development and regulation. He is a member of the NHS Stakeholder Forum and co-founder of Life Sciences UK.	G Steven Burrill G Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves on the boards of directors of AliveCor, Catalyst Biosciences, Depomed, NewBridge, Novadaq, Proventys, Targacept and XDx. Previously he served as chairman of the boards of BioImagene, Abunda Nutrition and Pharmasset. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the life sciences industries worldwide. He won Scrip's Lifetime Achievement Award in 2011.
Laura Brown Dr Laura Brown is an independent pharmaceutical project management and training consultant, and course director for the MSc programme in clinical research at the University of Cardiff’s School of Pharmacy. She has more than 16 years of experience of managing projects in the pharmaceutical industry. She has worked in project management for several companies including Wellcome, Hoechst Marion Roussel, Good Clinical Research Practices and Phoenix International. She is also co-author of two books on project management, including Pharmaceutical Project Management.	Antony Butler Antony Butler was Japan’s representative at PhRMA until the end of April 2006. Before joining PhRMA in 2001, he was vice-president for business development at Pharmacia (and Pharmacia & Upjohn), having served previously as vice-president for Japan, Europe and Latin America at the company. Mr Butler began his pharmaceutical career in 1966 at the Upjohn Company, joining its international division in 1975, for which he worked in Africa, Europe, Latin America, the US and Japan.
Katrina Campion Katrina Campion is senior clinical research manager for GlaxoSmithKline in Australia and president and chair of ARCS Australia, a professional society for those who work in the therapeutics industry in the Asia Pacific region. She was elected to the ARCS board nearly 10 years ago and this is her fourth year as president. She has helped to shape ARCS’ strategic direction and been involved in the growth of this not-for-profit organisation for clinical research professionals. In her current role, she provides leadership and management of GSK’s clinical research activities in Australia and New Zealand.	Gerhard Fortwengel Dr Gerhard Fortwengel has been involved in Clinical Research for more than 20 years. Prior to returning to academia in 2010 (University of Applied Sciences and Arts, Hanover), he worked in pharmaceutical industry, mainly in clinical research and quality assurance holding leadership positions. His particular interest is with clinical and regulatory compliance within clinical research projects.
Trevor Jones CBE Professor Trevor Jones is a director of Allergan, Sigma-Tau, VeronaPharma, ReNeuron and Synexus. Between 1987 and 1994, he was a main board director of The Wellcome Foundation, where he was responsible for R&D. He is a founder member of the Medicines for Malaria Venture and in 2004 was appointed to the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health. He was previously a member of the UK Medicines Commission and director general of the Association of the British Pharmaceutical Industry. He won Scrip’s Lifetime Achievement Award in 2005.	Jonathan Knowles Professor Jonathan Knowles, former head of group research and a member of the Executive Committee at Roche up to 2009, is a global opinion leader in personalised medicine. He was a member of the Board at Genentech for the last 12 years as well as a member of the Chugai Pharmaceuticals Board. He holds a Distinguished Professorship in Personalized Health Care at FIMM (Finnish Institute for Molecular Medicine) at the University of Helsinki, was recently appointed Professor of Translational Research at EPFL in Switzerland and has been appointed to a visiting chair at the University of Oxford. From the beginning of 2010, he joined the Board of Caris Life Sciences; a molecular diagnostics company based in Texas, and in May 2010 assumed the role of Caris’ chief scientific officer. He won Scrip's Lifetime Achievement Award in 2010.
Rolf Krebs Professor Rolf Krebs joined Bayer in Wuppertal in 1976 and became head of Bayer’s Worldwide Pharmaceutical R&D Department and head of the Pharma Sector R&D Coordination Committee in 1984. From 1986 to 1989 he was vice-general director of Bayer Italy, and in 1989 he became a managing partner at C H Boehringer Sohn and vice-chairman of the board of managing directors at Boehringer Ingelheim. In 2001, he became chairman of the board of directors. From 1998 to 2000 he was president of EFPIA and from 2000 to 2002 he was president of the IFPMA. He is currently chairman of the supervisory board of Epigenomics, Ganymed Pharmaceuticals, Merck KGaA and a member of the board of Air Liquide/Paris. He won Scrip’s Lifetime Achievement Award in 2006.	Viren Mehta Dr Viren Mehta is the founder of Mehta Partners, an independent advisory firm to pharma and biotechnology companies worldwide. For over 20 years his work has focused on global strategic consulting as well as research for the investment industry. Prior to pioneering the in-depth science-driven valuation of the biopharma industry, Dr Mehta was a part of the strategic planning team of the international division at Merck & Co and earned a Doctor of Pharmacy at the University of Southern California, and an MBA from the University of California, Los Angeles.
Phornvit Phacharintanakul Phornvit Phacharintanakul is chairman of Strategic Business Partners in Bangkok, Thailand. Until the end of 2004 he was chairman of the board at Aventis Thailand, where he previously held a range of posts including managing director and marketing manager. Before joining Aventis, he was on the secretariat of the United Nations Economic Commission for Asia and the Pacific. Mr Phacharintanakul also acts as an expert advisor for the Thailand Center of Excellence for Life Sciences.	Peter Pitts Peter Pitts is president of the Center for Medicine in the Public Interest. From 2002 to 2004, a former member of the United States Senior Executive Service, Peter was the FDA’s associate commissioner for external relations, serving as senior communications and policy adviser to the commissioner. He supervised FDA's Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce and is a Special Government Employee (SGE) consultant to the FDA’s Risk Communications Advisory Committee where he is advising the FDA on regulatory issues in the sphere of social media.
Robert Ruffolo Dr Robert Ruffolo is currently president of Ruffolo Consulting, a pharmaceutical and biotechnology consulting company. He retired in 2008 as president of research and development at Wyeth Pharmaceuticals and senior vice-president of Wyeth Corporation. Before joining Wyeth, Dr Ruffolo spent 17 years with SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline), where he played a significant role in the discovery and development of a number of products, including the heart failure drug, carvedilol (Coreg/Dilatrend), and the Parkinson's disease therapy ropinirole (Requip). Dr Ruffolo was awarded Scrip's Lifetime Achievement Award in 2008.	Robert Spiegel Dr Robert Spiegel is the founder of Spiegel Consulting, an independent advisory firm to pharma and biotechnology companies, and serves as an advisor to Warburg Pincus. He retired in 2009 as chief medical officer at Schering-Plough. With more than 25 years of experience in the pharmaceutical industry he played a significant role in the development of novel biologics and drugs as senior vice-president of Worldwide Clinical Research. He is a Fellow of the American College of Physicians and has received numerous awards and fellowships including the NIH Biomedical Research Support Program Grant, Leukemia Society of America Fellowship, and the Mary Ellis Bell Prize of the University of Pennsylvania. He serves on the Boards of numerous biotechnology companies and non-profit organisations. He is an Associate Fellow in the University of Pennsylvania Center for Bioethics.
Brian Tempest Dr Brian Tempest has worked in the Pharmaceutical Industry for the last 42 years and in that time has managed healthcare businesses around the globe. Between 1995 and 2007 held senior executive positions, including president, CEO and vice-chairman at Ranbaxy Laboratories. Between 2009 and 2011 he was chairman of Indian investment bank Religare Capital Markets. Previously Dr Tempest was Far East regional director for GlaxoSmithKline in the Far East, Middle East and Africa. Today, as chairman of Hale & Tempest, he advises companies, banks, investment funds, private equity and high net worth individuals on their strategy in Asia based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Dr Tempest is non-executive director of SRL, the largest Indian diagnostics company, Fortis Healthcare, and Glenmark Pharmaceuticals.	Paul Wathall Dr Wathall has worked in clinical trials for 15 years, nine years of which were spent managing a NHS cardiology research unit. He was formerly a Department of Health funded Research Training Fellow during which time he completed his PhD at the University of York. In 2006, he became senior clinical trials manager for HCA International, following which he was elected to the Board of Directors of the Institute of Clinical Research, where he is currently chief executive officer.